Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
and Saeys teams. In this research project you will develop and apply algorithms to link clinical phenotypes of metastasis to molecular phenotypes in mouse models. It is known that metastases exhibit
-
package based on expertise and experience At SWITCH we have particular attention for the career development goals of our people and actively support the ambitions of our lab members in the lab and beyond
-
development. Competitive salary and benefits. Full‑time, indefinite contract with flexible working arrangements. How to apply Apply via the online application tool (https://jobs.vib.be/apply/132489 ). Include
-
Chart tumour evolution using cutting-edge long-read and single-cell multiomics Who we are The Integrative Cancer Genomics lab (Jonas Demeulemeester) is embedded within the VIB – KU Leuven Center
-
homeostasis to disease. About the role We are seeking a motivated software developer who wants to join the Saeys lab within the VIB-UGent Center for Inflammation Research to help develop, maintain and extend
-
leading research institute focused on understanding cancer biology and developing innovative therapies. Our Bioinformatics & AI Expertise Unit provides advanced computational support to multiple research
-
Saelens team. Research Project In this research project you will develop probabilistic deep-learning models that automatically extract biological and statistical knowledge from in vivo perturbational omics
-
Leuven, Belgium and is part of the VIB-KU Leuven Center for Neuroscience . The Verstreken lab is developing advanced multielectrode array systems to mimic human brain circuits relevant to neurodegenerative
-
for Neuroscience . The Verstreken lab is developing advanced multielectrode array systems to mimic human brain circuits relevant to neurodegenerative disease. They are also conducting advanced CRISPR screens
-
antibody specificity profiling. KEY RESPONSIBILITIES You’ll join a small team advancing a new screening platform focused on therapeutic antibody specificity. The aim is to deploy this newly developed assay